Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDV8H5
|
|||
| Drug Name |
AlphaMedix
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [1] | |
| Company |
Orano Med; RadioMedix
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor (SSTR) | Target Info | Activator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03466216) Phase 1 Study of AlphaMedix in Adult Subjects With SSTR (+) NET. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Orano Med. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.